AR076772A1 - Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe - Google Patents
Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfeInfo
- Publication number
- AR076772A1 AR076772A1 ARP100101684A ARP100101684A AR076772A1 AR 076772 A1 AR076772 A1 AR 076772A1 AR P100101684 A ARP100101684 A AR P100101684A AR P100101684 A ARP100101684 A AR P100101684A AR 076772 A1 AR076772 A1 AR 076772A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydrobenzofuran
- pyrrolidin
- methyl
- fluoro
- product prepared
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 6
- -1 7-fluoro-2-methyl-2,3-dihydrobenzofuran-4-yl Chemical group 0.000 abstract 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 5
- 229940080818 propionamide Drugs 0.000 abstract 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 abstract 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 abstract 2
- MQTIJMDLIUJQFP-ABLWVSNPSA-N 2-methyl-n-[(3s)-1-(2-methyl-2,3-dihydro-1-benzofuran-4-yl)pyrrolidin-3-yl]propanamide Chemical compound C1[C@@H](NC(=O)C(C)C)CCN1C1=CC=CC2=C1CC(C)O2 MQTIJMDLIUJQFP-ABLWVSNPSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- FMPLMLGQGLTMRJ-UHFFFAOYSA-N methyl n-pyrrolidin-3-ylcarbamate Chemical compound COC(=O)NC1CCNC1 FMPLMLGQGLTMRJ-UHFFFAOYSA-N 0.000 abstract 1
- ZQSHHQGGPDMJTD-UEWDXFNNSA-N n-[(3s)-1-(2-ethyl-2,3-dihydro-1-benzofuran-4-yl)pyrrolidin-3-yl]acetamide Chemical compound O1C(CC)CC2=C1C=CC=C2N1CC[C@H](NC(C)=O)C1 ZQSHHQGGPDMJTD-UEWDXFNNSA-N 0.000 abstract 1
- FTKWDAIGUVLREA-KFJBMODSSA-N n-[(3s)-1-(2-methyl-2,3-dihydro-1-benzofuran-4-yl)pyrrolidin-3-yl]acetamide Chemical compound O1C(C)CC2=C1C=CC=C2N1CC[C@H](NC(C)=O)C1 FTKWDAIGUVLREA-KFJBMODSSA-N 0.000 abstract 1
- TZGNHIPLUIQXHB-YUZLPWPTSA-N n-[(3s)-1-(2-methyl-2,3-dihydro-1-benzofuran-4-yl)pyrrolidin-3-yl]cyclopropanecarboxamide Chemical compound N([C@H]1CCN(C1)C1=CC=CC2=C1CC(O2)C)C(=O)C1CC1 TZGNHIPLUIQXHB-YUZLPWPTSA-N 0.000 abstract 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un derivado 1-(2-aIquiI-2,3-dihidro-benzofuran-4-iI)-pirroIidin-3-iIaminoaciIo, caracterizado porque el compuesto se selecciona del grupo constituido por (i) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)acetamida; (ii) 2,2,2-trifluoro-N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)acetamida; (iii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)propionamida; (iv) 2-fluoro-N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)propanamida; (v) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)butiramida; (vi) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)isobutiramida; (vii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)ciclopropanocarboxamida; (viii) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-iI)pentanamida; (ix) N-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)-2-metilbutanamida; (x) (3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-ilcarbamato de metilo; (xi) (3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-ilcarbamato de etilo; (xii) 1-etil-3-((3S)-1-(7-fluoro-2-metil-2,3-dihidrobenzofuran-4-il)pirroIidin-3-il)urea; (xiii) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xiv) 2,2,2-trifluoro-N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xv) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-iI)propionamida; (xvi) N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)isobutiramida; (xvii) N-((3S)-1 -(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)ciclopropanocarboxamida; (xviii) 3-metil-N-((3S)-1-(2-metil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)butanamida; (xix) N-((3S)-1-(2-etil-2,3-dihidrobenzofuran-4-il)pirrolidin-3-il)acetamida; (xx) N-((3S)-1-(2-etil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-il)propionamida; y (xxi) N-((3S)-1-(2-propil-2,3-dihidrobenzofuran-4-iI)pirrolidin-3-il)propionamida; y una sal, solvato, hidrato farmacéuticamente aceptable, o una forma enantiomérica de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162731A EP2266975A1 (en) | 2009-06-15 | 2009-06-15 | 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076772A1 true AR076772A1 (es) | 2011-07-06 |
Family
ID=41136948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101684A AR076772A1 (es) | 2009-06-15 | 2010-05-14 | Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120088809A1 (es) |
| EP (2) | EP2266975A1 (es) |
| JP (1) | JP2012530097A (es) |
| KR (1) | KR20120036840A (es) |
| CN (1) | CN102803253A (es) |
| AR (1) | AR076772A1 (es) |
| AU (1) | AU2010261961A1 (es) |
| CA (1) | CA2762304A1 (es) |
| CL (1) | CL2011003165A1 (es) |
| MX (1) | MX2011013073A (es) |
| PE (1) | PE20120488A1 (es) |
| RU (1) | RU2012101227A (es) |
| TW (1) | TW201102381A (es) |
| UY (1) | UY32654A (es) |
| WO (1) | WO2010145989A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921615A1 (en) * | 2013-09-09 | 2015-03-12 | Chu Sainte-Justine | New marker for the classification, diagnosis and treatment of scoliosis |
| EP3083555B1 (en) | 2013-12-18 | 2018-10-03 | Monsanto Technology LLC | Processes for the diazotization of 2,5-dichloroanilines |
| CN116253704B (zh) * | 2021-12-10 | 2024-11-26 | 中国科学院昆明植物研究所 | Paeoveitol D衍生物及其药物组合物和其制备方法与其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU763963B2 (en) * | 1999-06-30 | 2003-08-07 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| US20090209638A1 (en) * | 2006-05-22 | 2009-08-20 | Gunther Birznieks | Treatment for depressive disorders |
-
2009
- 2009-06-15 EP EP09162731A patent/EP2266975A1/en not_active Withdrawn
-
2010
- 2010-05-14 AR ARP100101684A patent/AR076772A1/es unknown
- 2010-05-25 UY UY0001032654A patent/UY32654A/es unknown
- 2010-06-04 TW TW099118105A patent/TW201102381A/zh unknown
- 2010-06-10 RU RU2012101227/04A patent/RU2012101227A/ru unknown
- 2010-06-10 KR KR1020117029690A patent/KR20120036840A/ko not_active Withdrawn
- 2010-06-10 CA CA2762304A patent/CA2762304A1/en not_active Abandoned
- 2010-06-10 EP EP10725121A patent/EP2443108A1/en not_active Withdrawn
- 2010-06-10 WO PCT/EP2010/058178 patent/WO2010145989A1/en not_active Ceased
- 2010-06-10 US US13/378,160 patent/US20120088809A1/en not_active Abandoned
- 2010-06-10 MX MX2011013073A patent/MX2011013073A/es not_active Application Discontinuation
- 2010-06-10 CN CN2010800265089A patent/CN102803253A/zh active Pending
- 2010-06-10 PE PE2011002080A patent/PE20120488A1/es not_active Application Discontinuation
- 2010-06-10 JP JP2012515437A patent/JP2012530097A/ja active Pending
- 2010-06-10 AU AU2010261961A patent/AU2010261961A1/en not_active Abandoned
-
2011
- 2011-12-15 CL CL2011003165A patent/CL2011003165A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010145989A1 (en) | 2010-12-23 |
| EP2266975A1 (en) | 2010-12-29 |
| CN102803253A (zh) | 2012-11-28 |
| EP2443108A1 (en) | 2012-04-25 |
| UY32654A (es) | 2010-11-30 |
| RU2012101227A (ru) | 2013-07-27 |
| CA2762304A1 (en) | 2010-12-23 |
| MX2011013073A (es) | 2012-02-28 |
| PE20120488A1 (es) | 2012-04-27 |
| TW201102381A (en) | 2011-01-16 |
| JP2012530097A (ja) | 2012-11-29 |
| AU2010261961A1 (en) | 2011-12-08 |
| CL2011003165A1 (es) | 2012-07-06 |
| US20120088809A1 (en) | 2012-04-12 |
| KR20120036840A (ko) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2840080T3 (da) | Nitrogenholdig heterocyklisk forbindelse eller salt deraf | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| TW200745111A (en) | New compounds | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| WO2004076386A3 (en) | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors | |
| CA2495967A1 (fr) | Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent | |
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| PE20091577A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| DE602004021959D1 (de) | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor | |
| BRPI0414581A (pt) | derivados de benzimidazol: preparação e aplicações farmacêuticas | |
| EA201170742A1 (ru) | Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения | |
| PE20130230A1 (es) | Derivados de carboxamidas n-azabiciclicas y su preparacion | |
| GEP20166443B (en) | Heterocyclic compound and use thereof | |
| WO2008105383A1 (ja) | ピラゾール誘導体およびその医薬用途 | |
| MX358961B (es) | Compuestos de tetraciclina sustituidos con fluor en c7. | |
| CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
| CL2007003346A1 (es) | Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras | |
| WO2011025982A3 (en) | Tetracycline compounds | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| WO2010129057A3 (en) | Tetracycline compounds | |
| ATE440833T1 (de) | Antithrombotische diamide | |
| AR076772A1 (es) | Compuestos 1-(2-alquil-2-3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; producto medicinal preparado a partir del mismo y su uso; composicion farmaceutica que comprende a dicho compuesto; producto medicinal preparado a partir de esta y su uso; procedimiento de tratamiento o prevencion de enfe | |
| AR062112A1 (es) | Derivados ciclicos como moduladores de la actividad del receptor de quimiocina | |
| AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |